Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

doi:10.1038/s41591-021-01248-2

Published Erratum

. 2021 Mar;27(3):561.

doi: 10.1038/s41591-021-01248-2.

Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A Fraietta^{1

2

3}, Simon F Lacey^#^{1

2

3}, Elena J Orlando^#⁴, Iulian Pruteanu-Malinici⁴, Mercy Gohil², Stefan Lundh², Alina C Boesteanu², Yan Wang², Roddy S O'Connor², Wei-Ting Hwang⁵, Edward Pequignot², David E Ambrose², Changfeng Zhang², Nicholas Wilcox², Felipe Bedoya², Corin Dorfmeier², Fang Chen², Lifeng Tian², Harit Parakandi², Minnal Gupta², Regina M Young², F Brad Johnson¹, Irina Kulikovskaya², Li Liu², Jun Xu², Sadik H Kassim⁴, Megan M Davis^{1

2}, Bruce L Levine^{1

2}, Noelle V Frey^{2

6}, Donald L Siegel^{1

2

7}, Alexander C Huang^{3

8}, E John Wherry^{3

8}, Hans Bitter⁴, Jennifer L Brogdon⁴, David L Porter^{1

6}, Carl H June^{1

2

3}, J Joseph Melenhorst^{9

10

11}

Affiliations

¹ Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
³ Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.
⁴ Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
⁵ Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.
⁶ Division of Hematology-Oncology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁷ Division of Transfusion Medicine and Therapeutic Pathology, University of Pennsylvania, Philadelphia, PA, USA.
⁸ Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁹ Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.
¹⁰ Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.
¹¹ Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.

^# Contributed equally.

PMID: 33547459
DOI: 10.1038/s41591-021-01248-2

Published Erratum

Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A Fraietta et al. Nat Med. 2021 Mar.

. 2021 Mar;27(3):561.

doi: 10.1038/s41591-021-01248-2.

Authors

Affiliations

¹ Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
³ Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.
⁴ Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
⁵ Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.
⁶ Division of Hematology-Oncology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁷ Division of Transfusion Medicine and Therapeutic Pathology, University of Pennsylvania, Philadelphia, PA, USA.
⁸ Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁹ Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.
¹⁰ Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.
¹¹ Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.

^# Contributed equally.

PMID: 33547459
DOI: 10.1038/s41591-021-01248-2

No abstract available

PubMed Disclaimer

Erratum for

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ. Fraietta JA, et al. Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30. Nat Med. 2018. PMID: 29713085 Free PMC article.

Cited by

Role of CAR T Cell Metabolism for Therapeutic Efficacy.
Rial Saborido J, Völkl S, Aigner M, Mackensen A, Mougiakakos D. Rial Saborido J, et al. Cancers (Basel). 2022 Nov 4;14(21):5442. doi: 10.3390/cancers14215442. Cancers (Basel). 2022. PMID: 36358860 Free PMC article. Review.
Light-inducible T cell engagers trigger, tune, and shape the activation of primary T cells.
Jaeger M, Anastasio A, Chamy L, Brustlein S, Vincentelli R, Durbesson F, Gigan J, Thépaut M, Char R, Boussand M, Lechelon M, Argüello RJ, Marguet D, He HT, Lasserre R. Jaeger M, et al. Proc Natl Acad Sci U S A. 2023 Sep 26;120(39):e2302500120. doi: 10.1073/pnas.2302500120. Epub 2023 Sep 18. Proc Natl Acad Sci U S A. 2023. PMID: 37722050 Free PMC article.
The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
Mehra V, Chhetri JB, Ali S, Roddie C. Mehra V, et al. Biology (Basel). 2023 Nov 11;12(11):1419. doi: 10.3390/biology12111419. Biology (Basel). 2023. PMID: 37998018 Free PMC article. Review.
AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival.
Mehra V, Agliardi G, Dias Alves Pinto J, Shafat MS, Garai AC, Green L, Hotblack A, Arce Vargas F, Peggs KS, van der Waart AB, Dolstra H, Pule MA, Roddie C. Mehra V, et al. J Immunother Cancer. 2023 Sep;11(9):e007002. doi: 10.1136/jitc-2023-007002. J Immunother Cancer. 2023. PMID: 37709295 Free PMC article.
Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products.
Durkee-Shock J, Lazarski CA, Jensen-Wachspress MA, Zhang A, Son A, Kankate VV, Field NE, Webber K, Lang H, Conway SR, Hanley PJ, Bollard CM, Keller MD, Schwartz DM. Durkee-Shock J, et al. Mol Ther Methods Clin Dev. 2022 Jun 9;25:439-447. doi: 10.1016/j.omtm.2022.04.013. Epub 2022 Apr 29. Mol Ther Methods Clin Dev. 2022. PMID: 35506060 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Affiliations

Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Authors

Affiliations

Erratum for

Similar articles

Cited by

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources